INSYS Therapeutics, Inc.
http://www.insysrx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From INSYS Therapeutics, Inc.
Syngene Chief: Large Cap Biopharma Taking China 'Rotation' More Seriously
A material shift in China derisking discussions by big biopharma against the backdrop of the proposed US BIOSECURE Bill is seen presenting opportunities for Syngene, though the tight US biotech funding environment dampened demand for the Indian CRDMO’s R&D services in Q4.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Explained: How China’s Public Payer Wants To Define Innovative Drugs
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter revealed during a recent industry event. The disclosure has unnerved pharma companies, which have been hit by sharp drug price discounts that were required by the public payer in exchange for reimbursement coverage.
Merck KGaA Is Latest Partner For C4 Therapeutics’ Protein Degradation
New deal shows growing big pharma interest in protein degradation, with C4 expecting multiple in-house updates this year.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- NeoPharm, Inc.
- Fresenius Biotech GmbH
- Neovii Biotech GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice